Lysophosphatidylcholine-induced myocardial damage is inhibited by pretreatment with poloxamer 188 in isolated rat heart

Molecular and Cellular Biochemistry

Volumn 248, Issue 1-2, 2003, Pages 209-215

  Watanabe, Makino ^a   Okada, Takao ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardioprotection; Ischemia reperfusion; Langendorff perfusion; Left ventricular developed pressure; Left ventricular end diastolic pressure

Indexed keywords

ASPARTATE AMINOTRANSFERASE; LYSOPHOSPHATIDYLCHOLINE; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE ENDDIASTOLIC PRESSURE; ISOLATED HEART; MALE; NONHUMAN; RAT; REPERFUSION INJURY; SARCOLEMMA; VASOCONSTRICTION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LYSOPHOSPHATIDYLCHOLINES; MALE; MYOCARDIUM; PERFUSION; POLOXAMER; PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; SURFACE-ACTIVE AGENTS; TIME FACTORS; VENTRICULAR PRESSURE;

ANIMALIA;

EID: 0037966165     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024165125139     Document Type: Article

References (28)

1. Kuzuya T, Hoshida S, Kim Y: Detection of oxygen-derived free radical generation in the canine postischemic heart during late phase of reperfusion. Circ Res 66: 1160-1165, 1990
2. Ambrosio G, Tritto I: Reperfusion injury: Experimental evidence and clinical implications. Am Heart J 138: S69-S75, 1999
3. Bernhard H, Bernhard FB: Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC 58125, aggravates postischemic cardiac dysfunction, independent of COX function. Naunyn-Schmiedberg's Arch Pharmacol 363: 233-240, 2001
4. Yoshida K, Yamasaki Y, Kawashima S: Calpain activity alters in rat myocardial subfractions after ischemia or reperfusion. Biochim Biophys Acta 1182: 215-220, 1993
5. Sorimachi Y, Harada K, Saido TC, Ono T, Kawashima S, Yoshida K: Downregulation of calpastatin in rat heart after brief ischemia and reperfusion. J Biochem 122: 743-748, 1997
6. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, Yacoub MH: Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation 104(suppl I): I-308-I-313, 2001
7. Zhao ZQ, Velez DA, Wang NP, Hewan-Lowe KO, Nakamura M, Guyton RA: Progressively developed myocardial apoptoic cell death during late phase of reperfusion. Apoptosis 6: 279-290, 2001
8. Wang GU, Zhou Z, Klein JB, Kang YJ: Inhibition of hypoxia/reoxygenation-induced apoptosis in metalloyhionein-overexpressing cardiomyocytes. Am J Physiol Heart Circ Physiol 280: H2292-H2299, 2001
9. Watanabe M, Ochi R: Lysophosphatidylcholine activated two inward currents in human aortic endothelial cells. Jpn J Physiol 50(suppl): S58, 2000
10. Ochi R, Song Y, Tateyama MA, Tateyama M: Electroporation of cardiac muscle: Modulation by lysolipids, surfactants and polyethylene glycol. Jpn J Electrocardiol 20(suppl 3): 20-23, 2000
11. Schmolka IR: Physical basis for poloxamer interactions. Ann NY Acad Sci 720: 92-97, 1994
12. Sharma V, Stebe K, Murphy JC, Tung L: Poloxamer 188 decrease susceptibility of artificial lipid membranes to electroporation. Biophys J 71: 3229-3241, 1996
13. Lee RC, River LP, Pan FS, Li J, Wollmann L: Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo. Proc Natl Acad USA 89: 4524-4528, 1992
14. Koldgie FD, Farb A, Carlson GC, Wilson PS, Virmani R: Hyperoxic reperfusion is required to reduce infarct size after intravenous therapy with perfluorochemical (Fluosol-DA 20%) or its detergent component (poloxamer 188) in a poorly collateralized animal model. Absence of a role of polymorphonuclear leukocytes. J Am Coll Cardiol 24: 1098-1108, 1994
15. Palmer JS, Cromie WJ, Lee RC: Surfactant administration reduced testicular ischemia-reperfusion injury. J Urol 159: 2136-2139, 1998
16. Saegent CA, Vesterqvist O, Ogletree ML, Grover GJ: Effects of endogenous and exogenous lysophosphatidylcholine in isolated perfused rat heart. J Mol Cell Cardiol 25: 905-913, 1993
17. Magishi K, Kimura J, Kubo Y, Abiko Y: Exogenous lysophosphatidylcholine increases non-selective cation current in guinea-pig ventricular myocytes. Pflügers Arch 432: 345-350, 1996
18. Yu L, Netticadan T, Xu YJ, Panagia V, Dhalla NS: Mechanisms of lysophosphatidylcholine-induced increase in intracellular calcium in rat cardiomyocytes. J Pharmacol Exp Ther 286: 1-8, 1998
19. Woodley SL, Ikenouchi H, Barry WH: Lysophosphatidylcholine increases cytosolic calcium in ventricular myocytes by direct action on the sarcolemma. J Mol Cell Cardiol 23: 671-680, 1991
20. Hashizume H, Chen M, Ma H, Hara A, Yazawa K, Akahira M, Xiao CY, Abiko, Y: A new approach to the development of anti-ischemic drugs: Protective drugs against cell injury induced by lysophosphatidylcholine. Life Sci 62: 1695-1699, 1998
21. + current in rabbit coronary smooth muscle cells. J Vet Med Sci 63: 395-399, 2001
22. Flavahan NA: Lysophosphatidylcholine modifies G protein-dependent signaling in porcine endothelial cells. Am J Physiol 264 (Heart Circ Physiol 33): H722-H727, 1993
23. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Ohta Y, Yasue H: LPC in oxidized LDL elicits vasocontraction and inhibits endothelium-dependent relaxation. Am J Physiol 267 (Heart Circ Physiol 36): H2441-H2449, 1994
24. Otani H, Prasad MR, Jones RM, Das DK: Mechanism of membrane phospholipid degradation in ischemic-reperfused rat hearts. Am J Physiol 257 (Heart Circ Physiol 26): H252-H258, 1989
25. Sedlis SP, Sequeira JM, Altszuler HM: Coronary sinus lysophosphatidylcholine accumulation during rapid atrial pacing. Am J Cardiol 66: 695-698, 1990
26. Sedlis SP, Hom M, Sequeira JM, Tritel M, Gindea A, Ladenson JH, Jaffe AS, Esposito R: Time course of lysophosphatidylcholine release from ischemic human myocardium parallels the time course of early ischemic ventricular arrhythmia. Coron Artery Dis 8: 19-27, 1997
27. Daleau P: Lysophosphatidylcholine, a metabolite which accumulates early in myocardium during ischemia, reduces gap junctional coupling in cardiac cells. J Mol Cell Cardiol 31: 1391-1401, 1999
28. Sedlis SP: Mechanisms of ventricular arrhythmias in acute ischemia and reperfusion. Cardiovasc Clin 22: 3-18, 1992